Cytostatic Therapy of Chronic Myelogenous Leukemia: Review and Perspectives

  • R. Hehlmann

Abstract

There is general agreement that life expectancy of patients with chronic myelogenous leukemia (CML) has not changed much during the past 60 years [15, 20, 28, 35, 41]. CML has remained uniformly fatal, and the only curative therapy available up to now has been bone marrow transplantation [16, 58]. This, however, can be offered only to the small proportion of CML patients of sufficiently young age who have an HLA-compatible donor.

Keywords

Leukemia Interferon Methotrexate Melphalan Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Allan NC, Duvall E, Stockdill G (1978) Combination chemotherapy for chronic granulocytic leukemia. Lance 2: 523CrossRefGoogle Scholar
  2. 2.
    Baccarani M, Corbelli G, Tura S, and the Italian Cooperative Study Group on Chronic Myeloid Leukemia (1981) Early splenectomy and polychemotherapy versus polychemotherapy alone in chronic myeloid leukemia. Leuk Res 5: 149–157PubMedCrossRefGoogle Scholar
  3. 3.
    Bolin RW, Robinson WA, Sutherland J, Hamman RF (1982) Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia, Cancer 50: 1683–1687PubMedCrossRefGoogle Scholar
  4. 4.
    Brodsky I, Fuscaldo KE, Kahn SB, Conroy JF (1979) Myeloproliferative disorders. II. CML: Clonal evolution and its role in management. Leuk Res 3: 379–393PubMedCrossRefGoogle Scholar
  5. 5.
    Canellos GP, DeVita VT, Whang Peng J, Carbone PP (1971) Hematology and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood 38: 671–679PubMedGoogle Scholar
  6. 6.
    Canellos GP, Young RC, Niemann PE, DeVita VT Jr (1975) Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood 45: 197–203PubMedGoogle Scholar
  7. 7.
    Canellos GP, DeVita VT, Whang-Peng J, Chabner BA, Schein PS, Young RC (1976) Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood 47: 1003–9PubMedGoogle Scholar
  8. 8.
    Canellos GP (1977) The treatment of chronic granulocytic leukaemia. Clin Haemotol 6: 113–128Google Scholar
  9. 9.
    Coleman M, Silver R, Pajak T, Cavalli F, Rai KR, Kostin JE, Glidewell O, Holland JF (1980) Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood 55: 29–36PubMedGoogle Scholar
  10. 10.
    Conrad CFG (1973) Survival in chronic granulocytic leukemia: splenic irradiation vs. busulfan. Arch Intern Med 131: 684–685PubMedCrossRefGoogle Scholar
  11. 11.
    Cunningham I, Gee T, Dowling M et al. (1979) Results of treatment of Ph1-!- chronic myelogen¬ous leukemia with an intensive treatment regimen (L-5 protocol). Blood 53: 375–395PubMedGoogle Scholar
  12. 12.
    Dibromomannitol Cooperative Study Group (1973) Survival of chronic myeloid leukaemia patients treated by dibromomannitol. Eur J Cancer Clin Oncol 9: 583–589Google Scholar
  13. 13.
    Donehower RC (1982) Hydroxyurea. In: Chabner B (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 269–275Google Scholar
  14. 14.
    Foley HT, Bennett JM, Carbone PP (1969) Combination chemotherapy in accelerated phase of chronic granulocytic leukemia. Arch Intern Med 123: 166–170PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman JM (1978) Modern approaches to the management of chronic granulocytic leukemia. Semin Hematol 15: 420–430PubMedGoogle Scholar
  16. 16.
    Goldmann JM, Apperley JF, Jones L et al. (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–206CrossRefGoogle Scholar
  17. 17.
    Gollerkeri MP, Shah GB (1971) Management of chronic myeloid leukemia: a five year survey with a comparison of oral busulfan and splenic irradiation. Cancer 27: 596–601PubMedCrossRefGoogle Scholar
  18. 18.
    Goto T, Nishikori M, Arlin Z, Gee T, Kempin S, Burchenal J, Strife A, Wisniewski D, Lambek C, Little C, Jhanwar S, Chaganti R, Clarkson B (1982) Growth Characteristics of leukemic and normal hematopoietic cells in Ph, chronic myelogenous leukemia and effects of intensive treatment. Blood 59: 793–808PubMedGoogle Scholar
  19. 19.
    Griffin JD, Todd RF III, Ritz J, Nadier LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF (1983) Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 61: 85–91PubMedGoogle Scholar
  20. 20.
    Griffin JD (1986) Management of chronic myelogenous leukemia. Semin Hematol 23 [Suppl 1]: 20–26PubMedGoogle Scholar
  21. 21.
    Hadlock DC, Fortuny IE, McCullough J, Kennedy BJ (1975) Continuous flow centrifuge leukapheresis in the management of chronic myelogenous leukaemia. Br J Haematol 29: 443–453PubMedCrossRefGoogle Scholar
  22. 22.
    Hauch T, Logue G, Laszlo J, Cox E, Rundles W (1978) Treatment of chronic granulocytic leukemia with melphalan. Blood 51: 571–577PubMedGoogle Scholar
  23. 23.
    Haut A, Abbott WS, Wintrobe MM, Cartwright GE (1961) Busulfan in the treatment of chronic myelocytic leukemia: the effect of long term intermittent therapy. Blood 17: 1–19PubMedGoogle Scholar
  24. 24.
    Hayes D, Ellison R, Glidewell O, Holland J, Silver R (1974) Chemotherapy for the terminal phase of chronic myelocytic leukemia. Cancer Chemother Rep 58: 233–247Google Scholar
  25. 25.
    Hehlmann R, Heimpel H, Hossfeld DK, Kopeke W, Kolb HJ, Löffler H, Pralle H, Queißer W, Anger B, Bergmann L, Zankovich R, Meyer P, Essers U, Siegert W, Vaupel HA, Heiss F, Messerer D, Hasford J, Carbonell F, Heinze B, Burkhardt R, Georgii A (1987) Prospektive kontrollierte Studie zur Therapie der chronischen myeloischen Leukämie (CML). Onkologie 10: 28–33PubMedCrossRefGoogle Scholar
  26. 26.
    Hellriegel KP (1981) Therapie der Blastenkrise der chronischen myeloischen Leukämie. Ergeb¬nisse einer Phase-II-Studie mit Vindesin. Folia Haematol (Leipz) 108: 699–706Google Scholar
  27. 27.
    Hester JP, Waddell CC, Coltmann CA, Morrison FS, Stephens RL, Balcerzak SP, Baker LH, Timothy Chen T (1984) Response of chronic myelogenous leukemia patients to COAP-splenectomy. Cancer 54: 1977–1982PubMedCrossRefGoogle Scholar
  28. 28.
    Hossfeld DK, Cohnen G (1978) Die chronische myeloische Leukämie. In: Begemann H (ed) Leukämien. Springer, Berlin Heidelberg New York, pp 443–518 (Handbuch der Inneren Medi-zin, vol 2, part 6 )Google Scholar
  29. 29.
    Ihde DC, Canellos GP, Schwartz JH, DeVita VT (1976) Splenectomy in the chronic phase of chronic granulocytic leukemia. Ann Intern Med 84: 17–21PubMedGoogle Scholar
  30. 30.
    Janossy G, Woodruff RK, Pippard MJ et al. (1979) Relation of “lymphoid” phenotype and response to chemotherapy incorporating vincristine and prednisone in the acute phase of Ph1 positive leukemia. Cancer 43: 426–434PubMedCrossRefGoogle Scholar
  31. 31.
    Kantarjian HM, Velekoop L, McCredie KB, et al. (1985) Intensive combination chemotherapy (ROAP10) and spenectomy in the management of chronic myelogenous leukemia J Clin Oncol 3: 192–200PubMedGoogle Scholar
  32. 32.
    Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters R, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ (1985) Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66: 1326–1335PubMedGoogle Scholar
  33. 33.
    Kaung DT, Close HP, Whittington RM, Patno ME (1971) Comparison of Busulfan and cyclophosphamide in the treatment of chronic myelocytic leukemia. Cancer 27: 608–612PubMedCrossRefGoogle Scholar
  34. 34.
    Kennedy BJ (1972) Hydroxyurea therapy in chronic myelogenous leukemia. Cancer 29: 1052–1056PubMedCrossRefGoogle Scholar
  35. 35.
    Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia — new concepts. N. Engl J Med 304: 1201–1209 and 1269–1274Google Scholar
  36. 36.
    Koller A, Miller DM (1986) Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 315: 1433–1438PubMedCrossRefGoogle Scholar
  37. 37.
    Marks SM, Baltimore D, McCaffrey R (1978) Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic crisis of myelogenous leukemia: a co-operative study. N Engl J Med 298: 812–4PubMedCrossRefGoogle Scholar
  38. 38.
    Marmont AM, Damasio EE (1973) The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine. Acta Haematol 50: 1–8PubMedCrossRefGoogle Scholar
  39. 39.
    Medical Research Council’s Working Party for Therapeutic Trials in Leukemia (1968) Chronic granulocytic leukemia: comparison of radiotherapy and busulfan therapy. Br Med J [Clin Res] 1: 201–208CrossRefGoogle Scholar
  40. 40.
    Medical Research Council’s Working Party for Therapeutic Trials in Leukemia (1983) Randomized trial of splenectomy in Ph1-positive chronic granulocytic leukaemia, including an analysis of prognostic features. Br J Haematol 54: 415–430CrossRefGoogle Scholar
  41. 41.
    Minot GR, Buckman TE, Isaacs R (1924) Chronic myelogenous leukemia, age, incidence, duration and benefit derived from treatment. JAMA 82: 1489Google Scholar
  42. 42.
    Musshoff K, Boutis L, Obrecht P, Karsch T (1969) Die Lebenserwartung der chronischen myeloischen Leukämie in Abhängigkeit von individuellen und krankheitsspezifischen Faktoren und der Therapie. Klin Wochenschr 47: 179–183PubMedCrossRefGoogle Scholar
  43. 43.
    Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986) Alphas- Interferon — erste Behandlungsergebnisse bei der chronischen myeloischen Leukämie. Dtsch Med Wochenschr 111: 765–7676CrossRefGoogle Scholar
  44. 44.
    Pedersen-Bjergaard J, Worm AM, Hainau B (1977) Blastic transformation of chronic myelocytic leukaemia: clinical manifestations, prognostic factors and results of therapy. Scand J Haematol 18: 292–300PubMedCrossRefGoogle Scholar
  45. 45.
    Reinhard EH, Neely CL, Samples DM (1959) Radioactive phosporus in the treatment of chronic myelocytic leukemias: longterm results over a period of 15 years. Ann Intern Med 50: 942–958PubMedGoogle Scholar
  46. 46.
    Rosenthal S, Canellos GP, Whang-Peng, Gralnick HR (1977) Blast crisis of chronic granulocytic leukemia: morphologic variants and therapeutic implications. Am J Med 63: 542–547PubMedCrossRefGoogle Scholar
  47. 47.
    Rundles RW, Grizzle J, Bell WN, Corley CG, Frommeyer WB, Greenberg BG, Huguley CM, James GW, Jones R, Larsen WE, Loeb V, Leone LA, Palmer JG, Riser WH, Wilson SJ (1959) Comparison of chlorambucil and myleran in chronic lymphocytic and granulocytic leukemia. Am J Med 27: 424–432CrossRefGoogle Scholar
  48. 48.
    Schwartz JH, Canellos GP (1975) Hydroxyurea in the management of the hematologic complica¬tions of chronic granulocytic leukemia. Blood 46: 11–16PubMedGoogle Scholar
  49. 49.
    Schwarzenberg L, Mathe G, Pouillart P, Weiner R, Locour J, Genin J, Schneider M, de Vassal F, Hayat M, Amiel JL, Schlumberger JR, Jasmin C, Rosenfeld C (1973) Hydroxyurea, leukapheresis, and splenectomy in chronic myeloid leukemia at the problastic phase. Br Med J [Clin Res] 1: 700–703CrossRefGoogle Scholar
  50. 50.
    Sharp JC, Joyner MV, Wayne AW, Kemp J, Crofts M, Birch ADJ, McArthur G, Lai S, Sterndale H, Williams Y (1979) Karyotypic conversion in Ph-l-positive chronic myeloid leukemia with combination chemotherapy. Lancet 1: 1370–1372PubMedCrossRefGoogle Scholar
  51. 51.
    Smalley RV, Vogel J, Huguley CM, JUR, Miller D (1977) Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cyclespecific chemotherapy. Blood 50: 107–113PubMedGoogle Scholar
  52. 52.
    Sokal JE (1976) Evaluation of survival data for chronic myelocytic leukemia. Am J Hematol 1: 493–500PubMedCrossRefGoogle Scholar
  53. 53.
    Southeastern Cancer Chemotherapy Cooperative Study Group (1963) Comparison of 6-mercap- topurine and busulfan in chronic granulocytic leukemia. Blood 21: 89–100Google Scholar
  54. 54.
    Spiers ASD, Galton DAG, Kaur J, Goldman JM (1975) Thioguanine as primary treatment for chronic granulocytic leukaemia. Lancet 1: 829–832PubMedCrossRefGoogle Scholar
  55. 55.
    Spiers ASD, Goldman JM, Catovsky D, Costello C, Buskard NA, Galton DAG (1977) Multiple-drug chemotherapy for acute leukemia: the TRAMPCOL regimen: results in 86 patients. Cancer 40: 20–9PubMedCrossRefGoogle Scholar
  56. 56.
    Talpaz M, McCredie K, Mavligit GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689 - 692PubMedGoogle Scholar
  57. 57.
    Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069PubMedCrossRefGoogle Scholar
  58. 58.
    Thomas ED, Clift RA, Fefer A et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163PubMedGoogle Scholar
  59. 59.
    Tura S, Zaccaria A, Corbelli G et al. (1984) Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 54: 333–338CrossRefGoogle Scholar
  60. 60.
    Vallejos CS, McCredie KB, Brittin GM, Freireich EJ (1973) Biological effects of repeated leukapheresis of patients with chronic myelogenous leukemia. Blood 42: 925–933PubMedGoogle Scholar
  61. 61.
    Vallejos CS, Trujillo JM, Cork A, Bodey GP, McCredie KP, Freireich EJ (1974) Blastic crisis in chronic granulocytic leukemia: experience in 39 patients. Cancer 34: 1806–1812PubMedCrossRefGoogle Scholar
  62. 62.
    Wolf DJ, Silver RT, Coleman M (1978) Splenectomy in chronic myeloid leukemia. Ann Intern Med 89: 684–689PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. Hehlmann

There are no affiliations available

Personalised recommendations